Page last updated: 2024-12-06
estradiol-16
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
estradiol-16: RN given refers to the (16alpha)-isomer; RN for cpd without isomeric designation not avail 3/90 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 66421 |
CHEMBL ID | 1627567 |
SCHEMBL ID | 3357076 |
MeSH ID | M0174193 |
Synonyms (15)
Synonym |
---|
estra-1,5(10)-triene-3,16-diol, (16.alpha.)- |
1090-04-6 |
nsc19611 |
nsc-19611 |
estradiol-16beta |
(8s,9s,13r,14s,16r)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,16-diol |
CHEMBL1627567 |
nsc 19611 |
estradiol-16alpha |
estra-1,3,5(10)-triene-3,16-diol, (16alpha)- |
estradiol-16 |
SCHEMBL3357076 |
estra-1 ,3,5(10)-triene-3,16alpha-diol |
DTXSID101283179 |
(16alpha)-estra-1,3,5(10)-triene-3,16-diol |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (2)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID103554 | Growth response in cultures of MCF-7 (human breast cancer cell line) cells | 1997 | Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22 | Induction of the estrogen specific mitogenic response of MCF-7 cells by selected analogues of estradiol-17 beta: a 3D QSAR study. |
AID68899 | Estrogen receptor (ER) binding affinity | 1997 | Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22 | Induction of the estrogen specific mitogenic response of MCF-7 cells by selected analogues of estradiol-17 beta: a 3D QSAR study. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (9)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 6 (66.67) | 18.7374 |
1990's | 2 (22.22) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (11.11) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 27.49
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (27.49) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 10 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |